Blueprint Medicines Corp Net Income
| BPMCDelisted Stock | USD 129.46 0.11 0.09% |
As of the 15th of February 2026, Blueprint Medicines shows the Risk Adjusted Performance of 0.1715, downside deviation of 1.37, and Mean Deviation of 1.86. Blueprint Medicines Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Blueprint Medicines' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Blueprint Medicines' valuation are provided below:Blueprint Medicines Corp does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Blueprint |
Search Suggestions
| BP | BP PLC ADR | Company |
| BPOPM | Popular Capital Trust | Company |
| BPAVX | Boston Partners All Cap | Mutual Fund |
| BPI | Grayscale Funds Trust | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Blueprint Medicines Corp reported net income of (67.09 Million). This is 119.66% lower than that of the Biotechnology sector and 195.78% lower than that of the Health Care industry. The net income for all United States stocks is 111.75% higher than that of the company.
Blueprint Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Blueprint Medicines' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Blueprint Medicines could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics of similar companies.Blueprint Medicines is currently under evaluation in net income category among its peers.
Blueprint Fundamentals
| Return On Equity | -0.48 | |||
| Return On Asset | -0.0975 | |||
| Profit Margin | (0.28) % | |||
| Operating Margin | (0.28) % | |||
| Current Valuation | 8.25 B | |||
| Shares Outstanding | 64.58 M | |||
| Shares Owned By Insiders | 0.80 % | |||
| Shares Owned By Institutions | 99.20 % | |||
| Number Of Shares Shorted | 3.68 M | |||
| Price To Earning | 7.93 X | |||
| Price To Book | 24.44 X | |||
| Price To Sales | 14.89 X | |||
| Revenue | 508.82 M | |||
| Gross Profit | 542.35 M | |||
| EBITDA | 19.23 M | |||
| Net Income | (67.09 M) | |||
| Cash And Equivalents | 853.11 M | |||
| Cash Per Share | 14.28 X | |||
| Total Debt | 126.05 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 6.00 X | |||
| Book Value Per Share | 5.30 X | |||
| Cash Flow From Operations | (192.59 M) | |||
| Short Ratio | 0.62 X | |||
| Earnings Per Share | (2.51) X | |||
| Target Price | 130.29 | |||
| Number Of Employees | 682 | |||
| Beta | 0.83 | |||
| Market Capitalization | 8.37 B | |||
| Total Asset | 1.18 B | |||
| Retained Earnings | (2.41 B) | |||
| Working Capital | 481.88 M | |||
| Current Asset | 170.42 M | |||
| Current Liabilities | 18.64 M | |||
| Net Asset | 1.18 B |
About Blueprint Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Blueprint Medicines Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Blueprint Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Blueprint Medicines Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Blueprint Stock
If you are still planning to invest in Blueprint Medicines Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Blueprint Medicines' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |